Company: XAIR
Filing Date: 2025-02-14
Form Type: 424B5
Source: 0001493152-25-006903
Chunk: 7

Company: Beyond Air, Inc.
Filing Date: 2025-02-14
Form: 424B5
Chunk 7
---
 staff in carrying out safety procedures.

Our novel LungFit® platform can also deliver a high concentration (>150 ppm) of NO directly to the lungs, which we believe has the potential to eliminate microbial infections including bacteria, fungi and viruses, among others. We believe that current FDA-approved NO vasodilation treatments would have limited success in treating microbial infections given the low concentrations of NO being delivered (<100 ppm). Given that NO is produced naturally by the body as an innate immunity mechanism, at a concentration of 200 ppm, supplemental high dose NO should aid in the body’s fight against infection. Based on our preclinical studies and clinical trials, we believe that 150 ppm is the minimum therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date, neither the FDA nor comparable foreign regulatory agencies in other countries or regions have approved any NO formulation and/or delivery system for >80 ppm NO.

Corporate Information

We were incorporated on April 28, 2015 under Delaware law. On June 25, 2019, our name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc. Our principal executive offices are located at 900 Stewart Avenue, Suite 301, Garden City, New York 11530, and our telephone number is (516) 665-8200. Our website address is www.beyondair.net. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus.

| S-3 |

<div align='center'>THE OFFERING</div>

| Common                
 Stock Offered By Us   |     | Shares                                                                                                                              
 of our common stock having an aggregate offering price of up to $9,892,518.                                                         |
| Manner                
 of Offering           |     | “At                                                                                                                                 
 the market offering” that may be made from time to time through our agent, BTIG, LLC. See “Plan of Distribution”                    
 on page S-11 of this prospectus supplement.                                                                                         |
| Use                   
 of Proceeds           |     | We                                                                                                                                  
 currently intend to use the net proceeds from this offering primarily to further advance our pipeline of product candidates and for 
 working capital and general corporate purposes. See “Use of Proceeds” on page S-9 of this prospectus supplement.                    |
| Risk                  
 Factors               |     | Investing                                                                                                                           
 in our common stock involves significant risks. See “Risk Factors”